JPWO2022124331A1 - - Google Patents

Info

Publication number
JPWO2022124331A1
JPWO2022124331A1 JP2022568308A JP2022568308A JPWO2022124331A1 JP WO2022124331 A1 JPWO2022124331 A1 JP WO2022124331A1 JP 2022568308 A JP2022568308 A JP 2022568308A JP 2022568308 A JP2022568308 A JP 2022568308A JP WO2022124331 A1 JPWO2022124331 A1 JP WO2022124331A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568308A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022124331A1 publication Critical patent/JPWO2022124331A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/248—Xylanases
    • C12N9/2482—Endo-1,4-beta-xylanase (3.2.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022568308A 2020-12-08 2021-12-08 Pending JPWO2022124331A1 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020203449 2020-12-08
PCT/JP2021/045102 WO2022124331A1 (ja) 2020-12-08 2021-12-08 マクロファージ活性化剤

Publications (1)

Publication Number Publication Date
JPWO2022124331A1 true JPWO2022124331A1 (enExample) 2022-06-16

Family

ID=81973289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568308A Pending JPWO2022124331A1 (enExample) 2020-12-08 2021-12-08

Country Status (7)

Country Link
US (1) US20240009268A1 (enExample)
EP (1) EP4260866A4 (enExample)
JP (1) JPWO2022124331A1 (enExample)
CN (1) CN116710117A (enExample)
AU (1) AU2021398261A1 (enExample)
TW (1) TW202237169A (enExample)
WO (1) WO2022124331A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250026271A (ko) * 2022-06-22 2025-02-25 사이세이 파마 씨오., 엘티디. 노화 억제제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508544A (ja) * 1997-01-06 2001-06-26 信人 山本 インフルエンザに対する血清α−Ｎ−アセチルガラクトサミニダーゼの診断用および予後判定用ＥＬＩＳＡアッセイ
WO2012029954A1 (ja) * 2010-09-03 2012-03-08 国立大学法人徳島大学 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
JP2014511857A (ja) * 2011-04-07 2014-05-19 エフラナット リミテッド 医薬組成物のマクロファージ活性化因子
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5177001A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US6410269B1 (en) 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
US8747919B2 (en) 2011-09-14 2014-06-10 Saisei Mirai Clinic Pharmaceutical composition and method of preparing same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508544A (ja) * 1997-01-06 2001-06-26 信人 山本 インフルエンザに対する血清α−Ｎ−アセチルガラクトサミニダーゼの診断用および予後判定用ＥＬＩＳＡアッセイ
WO2012029954A1 (ja) * 2010-09-03 2012-03-08 国立大学法人徳島大学 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
JP2014511857A (ja) * 2011-04-07 2014-05-19 エフラナット リミテッド 医薬組成物のマクロファージ活性化因子
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法

Also Published As

Publication number Publication date
AU2021398261A9 (en) 2024-02-08
EP4260866A4 (en) 2025-01-01
AU2021398261A1 (en) 2023-07-06
WO2022124331A1 (ja) 2022-06-16
EP4260866A1 (en) 2023-10-18
US20240009268A1 (en) 2024-01-11
CN116710117A (zh) 2023-09-05
TW202237169A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
BR112023005462A2 (enExample)
BR112023012656A2 (enExample)
BR112021014123A2 (enExample)
BR112023009656A2 (enExample)
BR112022009896A2 (enExample)
BR112023008622A2 (enExample)
BR112022024743A2 (enExample)
BR112022026905A2 (enExample)
BR112023011738A2 (enExample)
BR112023004146A2 (enExample)
JPWO2022124331A1 (enExample)
BR112023006729A2 (enExample)
BR102021018859A2 (enExample)
BR102021015500A2 (enExample)
BR112021017747A2 (enExample)
BR112023016292A2 (enExample)
BR112023011610A2 (enExample)
BR112023008976A2 (enExample)
BR102021020147A2 (enExample)
BR102021018926A2 (enExample)
BR102021018167A2 (enExample)
BR102021017576A2 (enExample)
BR102021016837A2 (enExample)
BR102021016551A2 (enExample)
BR102021016375A2 (enExample)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118